LeMaitre Vascular, Inc. (NASDAQ:LMAT) CEO George W. Lemaitre sold 42,762 shares of the business’s stock in a transaction that occurred on Friday, May 7th. The stock was sold at an average price of $51.00, for a total value of $2,180,862.00. Following the sale, the chief executive officer now directly owns 2,592,425 shares in the company, valued at $132,213,675. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of LMAT opened at $47.95 on Thursday. LeMaitre Vascular, Inc. has a 12 month low of $23.40 and a 12 month high of $54.96. The stock has a fifty day moving average price of $50.30 and a 200-day moving average price of $44.25. The company has a current ratio of 2.30, a quick ratio of 1.27 and a debt-to-equity ratio of 0.23. The firm has a market cap of $987.34 million, a PE ratio of 51.56, a P/E/G ratio of 3.52 and a beta of 1.43.
LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Thursday, April 29th. The medical instruments supplier reported $0.28 EPS for the quarter, meeting the consensus estimate of $0.28. LeMaitre Vascular had a return on equity of 12.32% and a net margin of 15.41%. As a group, research analysts forecast that LeMaitre Vascular, Inc. will post 1 EPS for the current year.
Institutional investors and hedge funds have recently modified their holdings of the company. Fieldpoint Private Securities LLC purchased a new stake in shares of LeMaitre Vascular during the 4th quarter valued at $36,000. Steward Partners Investment Advisory LLC increased its position in shares of LeMaitre Vascular by 41.4% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,059 shares of the medical instruments supplier’s stock valued at $43,000 after acquiring an additional 310 shares during the period. Lazard Asset Management LLC acquired a new position in shares of LeMaitre Vascular in the 4th quarter valued at $47,000. Citigroup Inc. increased its position in shares of LeMaitre Vascular by 36.8% in the 4th quarter. Citigroup Inc. now owns 4,296 shares of the medical instruments supplier’s stock valued at $174,000 after acquiring an additional 1,155 shares during the period. Finally, Ensign Peak Advisors Inc increased its position in shares of LeMaitre Vascular by 1,750.0% in the 1st quarter. Ensign Peak Advisors Inc now owns 3,700 shares of the medical instruments supplier’s stock valued at $180,000 after acquiring an additional 3,500 shares during the period. Hedge funds and other institutional investors own 84.17% of the company’s stock.
A number of analysts recently issued reports on LMAT shares. Roth Capital boosted their price target on LeMaitre Vascular from $53.00 to $55.00 and gave the company a “neutral” rating in a report on Monday. Barrington Research boosted their price target on LeMaitre Vascular from $49.00 to $59.00 and gave the company an “outperform” rating in a report on Friday, April 30th. Zacks Investment Research lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Wednesday, May 5th. KeyCorp initiated coverage on LeMaitre Vascular in a report on Friday, February 12th. They set a “sector weight” rating for the company. Finally, Lake Street Capital upped their target price on LeMaitre Vascular from $55.00 to $65.00 and gave the stock a “buy” rating in a report on Friday, April 30th. Five analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. LeMaitre Vascular presently has a consensus rating of “Hold” and an average price target of $49.67.
About LeMaitre Vascular
LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system.
Further Reading: Economic Reports
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.